Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies – Markets Insider
|
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
Markets Insider Mustang has entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen … |
